$3.4 Billion is the total value of PFM Health Sciences, LP's 85 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 169.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CYTK | Buy | CYTOKINETICS INC | $112,928,000 | +238.2% | 3,159,701 | +87.3% | 3.32% | +217.5% |
| New | ERASCA INC | $98,172,000 | – | 5,191,405 | +100.0% | 2.89% | – | |
| New | CARIBOU BIOSCIENCES INC | $88,176,000 | – | 4,092,309 | +100.0% | 2.59% | – | |
| UHS | Buy | UNIVERSAL HLTH SVCS INCcl b | $72,061,000 | +1.1% | 520,786 | +6.9% | 2.12% | -5.2% |
| New | GILEAD SCIENCES INCcall | $67,314,000 | – | 963,700 | +100.0% | 1.98% | – | |
| DVAX | Buy | DYNAVAX TECHNOLOGIES CORP | $63,077,000 | +114.1% | 3,283,570 | +9.8% | 1.86% | +101.0% |
| New | UNITEDHEALTH GROUP INCcall | $61,424,000 | – | 157,200 | +100.0% | 1.81% | – | |
| New | SELECT SECTOR SPDR TRcall | $60,131,000 | – | 1,602,200 | +100.0% | 1.77% | – | |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $53,169,000 | +14.7% | 300,545 | +4.7% | 1.56% | +7.6% |
| New | HORIZON THERAPEUTICS PUB Lcall | $48,132,000 | – | 439,400 | +100.0% | 1.42% | – | |
| AZN | Buy | ASTRAZENECA PLCsponsored adr | $47,192,000 | +277.7% | 785,748 | +276.7% | 1.39% | +254.1% |
| PEN | Buy | PENUMBRA INC | $47,194,000 | +28.7% | 177,088 | +32.4% | 1.39% | +20.8% |
| ICLR | Buy | ICON PLC | $41,447,000 | +39.0% | 158,183 | +9.7% | 1.22% | +30.5% |
| NVAX | Buy | NOVAVAX INC | $40,883,000 | +29.1% | 197,208 | +32.3% | 1.20% | +21.2% |
| TMO | Buy | THERMO FISHER SCIENTIFIC INC | $40,817,000 | +132.3% | 71,442 | +105.1% | 1.20% | +117.8% |
| New | BRISTOL-MYERS SQUIBB COcall | $36,212,000 | – | 612,000 | +100.0% | 1.06% | – | |
| New | SOPHIA GENETICS SAordinary shares | $35,455,000 | – | 2,022,552 | +100.0% | 1.04% | – | |
| HRTX | Buy | HERON THERAPEUTICS INC | $32,001,000 | -6.2% | 2,993,546 | +36.1% | 0.94% | -12.1% |
| JNCE | Buy | JOUNCE THERAPEUTICS INC | $28,597,000 | +28.9% | 3,848,822 | +18.0% | 0.84% | +21.0% |
| New | NEUROCRINE BIOSCIENCES INCcall | $25,080,000 | – | 261,500 | +100.0% | 0.74% | – | |
| CTLT | New | CATALENT INC | $23,660,000 | – | 177,800 | +100.0% | 0.70% | – |
| ADAP | Buy | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $22,766,000 | +47.3% | 4,403,574 | +21.4% | 0.67% | +38.2% |
| ALLO | Buy | ALLOGENE THERAPEUTICS INC | $19,939,000 | +26.0% | 775,819 | +27.9% | 0.59% | +18.1% |
| ISEE | New | IVERIC BIO INC | $18,483,000 | – | 1,138,112 | +100.0% | 0.54% | – |
| New | STEVANATO GROUP S P A | $13,895,000 | – | 549,002 | +100.0% | 0.41% | – | |
| New | SIGHT SCIENCES INC | $10,976,000 | – | 483,538 | +100.0% | 0.32% | – | |
| AVIR | New | ATEA PHARMACEUTICALS INC | $10,607,000 | – | 302,532 | +100.0% | 0.31% | – |
| New | DYNAVAX TECHNOLOGIES CORPcall | $10,024,000 | – | 521,800 | +100.0% | 0.30% | – | |
| DXCM | New | DEXCOM INC | $9,576,000 | – | 17,510 | +100.0% | 0.28% | – |
| New | HUMANA INCcall | $8,172,000 | – | 21,000 | +100.0% | 0.24% | – | |
| DCPH | New | DECIPHERA PHARMACEUTICALS IN | $4,869,000 | – | 143,297 | +100.0% | 0.14% | – |
| New | MIRATI THERAPEUTICS INCcall | $2,654,000 | – | 15,000 | +100.0% | 0.08% | – | |
| BYSI | New | BEYONDSPRING INC | $2,548,000 | – | 161,697 | +100.0% | 0.08% | – |
| New | PROCEPT BIOROBOTICS CORP | $2,480,000 | – | 65,000 | +100.0% | 0.07% | – | |
| New | ADAPTIMMUNE THERAPEUTICS PLCcall | $1,509,000 | – | 291,800 | +100.0% | 0.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MOLINA HEALTHCARE INC | 41 | Q3 2023 | 2.2% |
| HCA HOLDINGS INC | 38 | Q3 2023 | 5.2% |
| HUMANA INC | 37 | Q3 2023 | 3.8% |
| EDWARDS LIFESCIENCES CORP | 36 | Q3 2023 | 3.3% |
| UNITEDHEALTH GROUP INC | 33 | Q3 2023 | 4.8% |
| PENUMBRA INC | 33 | Q3 2023 | 4.8% |
| AERIE PHARMACEUTICALS INC | 28 | Q2 2022 | 3.7% |
| TENET HEALTHCARE CORP | 27 | Q3 2023 | 2.3% |
| ELEVANCE HEALTH INC | 26 | Q3 2023 | 4.2% |
| ICON PLC | 26 | Q3 2023 | 2.5% |
View PFM Health Sciences, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adaptimmune Therapeutics PLC | February 14, 2023 | ? | ? |
| Arcus Biosciences, Inc. | February 14, 2023 | ? | ? |
| Axsome Therapeutics, Inc. | February 14, 2023 | ? | ? |
| Erasca, Inc. | February 14, 2023 | ? | ? |
| Generation Bio Co. | February 14, 2023 | ? | ? |
| IO Biotech, Inc. | February 14, 2023 | ? | ? |
| Jounce Therapeutics, Inc. | February 14, 2023 | ? | ? |
| Outset Medical, Inc. | February 14, 2023 | ? | ? |
| uniQure N.V. | February 14, 2023 | ? | ? |
| AERIE PHARMACEUTICALS INC | February 14, 2022 | ? | ? |
View PFM Health Sciences, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G | 2023-04-21 |
View PFM Health Sciences, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.